![](https://www.innovations-report.com/wp-content/uploads/2013/06/crop-in-fields-300x200.jpg)
![](https://www.innovations-report.com/wp-content/themes/innovation-report-2/assets/dist/img/placeholder-single-thumbnail.png)
Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease that leads to progressive joint deformity, disability, and occasionally premature death. Emerging evidence suggests the utility of histone deacetylase inhibitors (HDACi) in the treatment of chronic immune and inflammatory disorders such as rheumatoid arthritis. Several studies have shown the decreasing effect of selective HDAC6 inhibitors on the secretion of pro-inflammatory cytokines in vitro and a significant therapeutic response has been demonstrated in animal inflammatory disease models.
Further information: PDF
Bayerische Patentallianz GmbH
Phone: +49 89 5480177-0
Contact
Peer Biskup
As Germany's association of technology- and patenttransfer agencies TechnologieAllianz e.V. is offering businesses access to the entire range of innovative research results of almost all German universities and numerous non-university research institutions. More than 2000 technology offers of 14 branches are beeing made accessable to businesses in order to assure your advance on the market. At www.technologieallianz.de a free, fast and non-bureaucratic access to all further offers of the German research landscape is offered to our members aiming to sucessfully transfer technologies.